AI assistant
Moderna, Inc. — Director's Dealing 2022
May 2, 2022
30610_dirs_2022-05-02_f40e90b7-d039-4f3d-86fd-a502339346ff.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-04-28
Reporting Person: NABEL ELIZABETH G (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-04-28 | Common Stock | M | 703 | — | Acquired | 703 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-28 | Restricted Stock Units | $0 | M | 703 | Disposed | Common Stock (703) | Direct | |
| 2022-04-28 | Stock Option (Right to Buy) | $142.52 | A | 4061 | Acquired | Common Stock (4061) | Direct | |
| 2022-04-28 | Restricted Stock Units | $0 | A | 670 | Acquired | Common Stock (670) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: The shares subject to this restricted stock unit award vested in full on April 28, 2022.
F3: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
F4: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.